TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02243527

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: 6-weeks of inspiratory muscle training

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Inspiratory Muscle Training
Description: A sham training procedure that is meant to elicit no physiologic changes
Study: NCT02389946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orsiro DES
Description: Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience DES
Study: NCT01810146

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Digestive functions investigations
Study: NCT03340077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medicines Optimisation Review toolkit
Description: The Review tool consist of two items. 'My Clinic companion' and 'MOR consultation form'. 'My clinic companion' (see appendix 1) is a patient-orientated questionnaire that promotes self-review of medications and adherence and will facilitate the pharmacist consultation. The 'MOR consultation form' (see appendix 2), is designed to aid a structured patient consultation using available information from local databases, GP medication histories as well as that obtained directly from the patient. The form also identifies key care providers involved in the patient case, including prior consent to contact with information if required.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Pharmacist review of ART medications
Study: NCT00287833

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT00413166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide (ATO)
Description: Induction: 0.15 mg/kg daily IV beginning day 1
Study: NCT03008980

Intervention type: OTHER
Intervention: Diagnostic Test
Study: NCT04938531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will perform an entry passive exercise test within 48 hours of onset of severe sepsis. Patients then will perform 30-60 min supine passive cycle ergometry exercise 5 days/week.
Study: NCT03814629

Intervention type: DRUG
Group type: OTHER
Intervention: Weifuchun
Description: The treatment group（Weifuchun group）was given Weifuchun tablets, 4 tablets each time, 3 times a day, and 1 hour after meals. The control group(vitamin group) was given vitamin tablets (0.2 g), 4 tablets each time, 3 times a day, and 1 hour after a meal.
Study: NCT02573896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: 17.5 mg/m2/day of dinutuximab will be given for 4 consecutive days (days 1-4 of each course) via intravenous infusion over ten hours.
Study: NCT00287833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bowman-Birk inhibitor concentrate
Description: Given orally
Study: NCT02573896

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK Cells
Description: The designated dose of NK Cells will be infused on Day 5 by IV drip using a Y infusion set with a filter-less chamber. Cells should not be delivered at a rate faster than 10 ml/kg/hr (as determined by drip rate or syringe push rate), and should not take longer than one hour for total infusion time if possible.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg/m2/day of Lenalidomide will be given at Dose Level 4, once daily with or without food by mouth on days -6 through +14.
Study: NCT03948789

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging-controlled high-focussed ultrasound therapy
Description: Magnetic Resonance Imaging-controlled high-focussed ultrasound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myomectomy (laparoscopic or open surgical)
Description: Myomectomy (laparoscopic or open surgical)
Study: NCT00114114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Androgel placebo or 1.25, 2.5, 5. or 10\* gms topically each day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Androgel placebo or 1.25, 2.5, 5. or 10\* gms topically each day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Androgel placebo or 1.25, 2.5, 5. or 10\* gms topically each day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Androgel placebo or 1.25, 2.5, 5. or 10\* gms topically each day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Androgel placebo or 1.25, 2.5, 5. or 10\* gms topically each day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Androgel placebo or 1.25, 2.5, 5. or 10\* gms topically each day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin acetate
Description: 3.6 gms sc every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin acetate
Description: 3.6 gms sc every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin acetate
Description: 3.6 gms sc every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin acetate
Description: 3.6 gms sc every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin acetate
Description: 3.6 gms sc every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin acetate
Description: 3.6 gms sc every 4 weeks
Study: NCT00352781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine replacement therapy
Description: nicotine transdermal patches as per product monograph

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioural intervention
Description: Smoking cessation counselling and relapse prevention
Study: NCT03564665

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 400mg Magnesium Glycinate BID
Description: 400mg Magnesium Glycinate BID for 8 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID for 8 weeks.
Study: NCT01264965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: long acting oxycodone
Description: 10mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: extra strength acetaminophen
Description: 1,000 mg twice daily
Study: NCT00413166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide (ATO)
Description: Induction: 0.15 mg/kg daily IV beginning day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: 1. 12 mg/m2 one dose only (may be given on day 1 to 5 of induction)~2. If either ATRA or ATO are discontinued due to toxicity, idarubicin 12 mg/m2 x 2 doses will be administered once every 4 to 5 weeks (depending on the recovery of counts) until 28 weeks has elapsed from the Complete Recovery date.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: 1. 12 mg/m2 one dose only (may be given on day 1 to 5 of induction)~2. If either ATRA or ATO are discontinued due to toxicity, idarubicin 12 mg/m2 x 2 doses will be administered once every 4 to 5 weeks (depending on the recovery of counts) until 28 weeks has elapsed from the Complete Recovery date.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: 1. 12 mg/m2 one dose only (may be given on day 1 to 5 of induction)~2. If either ATRA or ATO are discontinued due to toxicity, idarubicin 12 mg/m2 x 2 doses will be administered once every 4 to 5 weeks (depending on the recovery of counts) until 28 weeks has elapsed from the Complete Recovery date.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Induction: 9 mg/m2 on day 1 of induction
Study: NCT02701920

Intervention type: DEVICE
Intervention: HeartLight hat
Description: HeartLight hat will be worn for up to 1 hour.

Intervention type: DEVICE
Intervention: The HeartLight hat with in-built sensor
Description: The HeartLight hat with in-built sensor will be worn.

Intervention type: DEVICE
Intervention: The HeartLight hat with in-built sensor
Description: The HeartLight hat with in-built sensor will be worn.

Intervention type: DEVICE
Intervention: The HeartLight hat with in-built sensor
Description: The HeartLight hat with in-built sensor will be worn.

Intervention type: DEVICE
Intervention: HeartLight
Description: Electronic stethoscope will be used to estimate heart rate with HeartLight sensor/hat

Intervention type: DEVICE
Intervention: HeartLight
Description: Electronic stethoscope will be used to estimate heart rate with HeartLight sensor/hat

Intervention type: DEVICE
Intervention: HeartLight
Description: Electronic stethoscope will be used to estimate heart rate with HeartLight sensor/hat

Intervention type: DEVICE
Intervention: HeartLight device
Description: HeartLight sensor/hat will be used with ECG/Pulse oximetry/electronic stethoscope

Intervention type: DEVICE
Intervention: HeartLight device
Description: HeartLight sensor/hat will be used with ECG/Pulse oximetry/electronic stethoscope

Intervention type: DEVICE
Intervention: HeartLight device
Description: HeartLight sensor/hat will be used with ECG/Pulse oximetry/electronic stethoscope

Intervention type: OTHER
Intervention: parental feedback
Description: Questionnaire

Intervention type: OTHER
Intervention: healthcare provider feedback
Description: Questionnaire
Study: NCT02181413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Ixazomib citrate capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ixazomib citrate placebo-matching capsules
Study: NCT03319654

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DNA fragmentation by TUNEL assay
Description: Direct DNA fragmentation testing with terminal deoxyuridine nick end labeling (TUNEL) assay.
Study: NCT02861989

Intervention type: OTHER
Intervention: qualitative study
Study: NCT03241420

Intervention type: DEVICE
Intervention: lung clearance index (LCI)
Description: Determine the utility and sensitivity of the lung clearance index (LCI) technique as a marker of lung injury/small airways disease in adults with chronic lung conditions compared to health adults, adjusting for age, sex, and smoking status.

Intervention type: DEVICE
Intervention: lung clearance index (LCI)
Description: Determine the utility and sensitivity of the lung clearance index (LCI) technique as a marker of lung injury/small airways disease in adults with chronic lung conditions compared to health adults, adjusting for age, sex, and smoking status.
Study: NCT02899754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lung Cancer Screening Decision Tool
Description: This will be a lung cancer screening decision support tool that is web based and provides patients with information about the potential benefits and harms associated with lung cancer screening and helps them to consider their personal values when making a decision about whether to initiate or continue with lung cancer screening.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: This will be a health message regarding prevention and healthy behavior that is not related to lung cancer screening but delivered in a similar modality and taking approximately the same amount of time as the LCSDecTool.
Study: NCT03996018

Intervention type: OTHER
Intervention: T-cell lymphocyte responses
Description: T-cell lymphocyte responses to human immunodeficiency virus (HIV) with and without concomitant herpesvirus infections (specifically, the persistence of HIV-specific human CD8 T-cells in the context of antiretroviral therapy (ART).

Intervention type: OTHER
Intervention: T-cell lymphocyte responses
Description: T-cell lymphocyte responses to human immunodeficiency virus (HIV) with and without concomitant herpesvirus infections (specifically, the persistence of HIV-specific human CD8 T-cells in the context of antiretroviral therapy (ART).
Study: NCT05359016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV testing of women for cervical cancer screening
Description: Women enrolled in this study will receive HPV testing for cervical cancer screening. They will be offered self-sampling. And also they will be offered voluntary Family Planning services, as appropriate.
Study: NCT04423211

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D CRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO
Study: NCT00269386

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00556673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol maleate/mometasone furoate
Description: Indacaterol maleate 250 μg / mometasone furoate 200 μg delivered via the Twisthaler device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol maleate/mometasone furoate
Description: Indacaterol maleate 250 μg / mometasone furoate 200 μg delivered via the Twisthaler device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to indacaterol maleate/mometasone furoate
Description: Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.
Study: NCT04423211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Given SC

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT
Study: NCT01874782

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial electrical stimulation
Description: TES: medical device TRANSAIR: electrodes placed on the forehead and over the mastoid processes using Velcro straps. Treatment protocol: six 30-minute sessions over a two-week period and stimulation variables (bipolar current; 1.0-3.0 milliamp (mA) amplitude, 3.5 ms duration and 77.5 Hz frequency).
Study: NCT00556673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to indacaterol maleate/mometasone furoate
Description: Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.
Study: NCT02592304

Intervention type: DEVICE
Group type: OTHER
Intervention: Dual energy computed tomography
Description: one extra scanning with a dual energy ct.
Study: NCT00722592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vintafolide
Description: 2.5 mg IV bolus on Days 1,3,5 and 15,17,19 of a 4-week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated liposomal doxorubicin (PLD)
Description: 50 mg/m\^2 (with dose based on ideal body weight for participants whose measured body weight is greater than their ideal body weight) intravenous infusion on Day 1 of a 4 week cycle. Dose reductions permitted for toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin (PLD)
Description: 50 mg/m\^2 (with dose based on ideal body weight for participants whose measured body weight is greater than their ideal body weight) intravenous infusion on Day 1 of a 4 week cycle. Dose reductions permitted for toxicity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EC20
Description: During the screening period, participants at centers with EC20 imaging capability will receive a single intravenous injection of 0.1 mg EC20 labeled with 20-25 mCi technetium-99m followed by an imaging procedure. A second injection and imaging may be done after all therapy with the study drugs is done.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EC20
Description: During the screening period, participants at centers with EC20 imaging capability will receive a single intravenous injection of 0.1 mg EC20 labeled with 20-25 mCi technetium-99m followed by an imaging procedure. A second injection and imaging may be done after all therapy with the study drugs is done.
Study: NCT02316093

Intervention type: OTHER
Intervention: Procedure: Gingival Crevicular Fluid, Saliva and Blood Sampling

Intervention type: OTHER
Intervention: Procedure: Gingival Crevicular Fluid, Saliva and Blood Sampling

Intervention type: OTHER
Intervention: Procedure: Gingival Crevicular Fluid, Saliva and Blood Sampling

Intervention type: OTHER
Intervention: Procedure: Gingival Crevicular Fluid, Saliva and Blood Sampling

Intervention type: OTHER
Intervention: Procedure: Gingival Crevicular Fluid, Saliva and Blood Sampling

Intervention type: OTHER
Intervention: Procedure: Gingival Crevicular Fluid, Saliva and Blood Sampling
Study: NCT04083040

Intervention type: PROCEDURE
Group type: OTHER
Intervention: transcatheter aortic valve implantation
Description: 1. Tilt angle.~2. Depth of implantation of the valve.~3. Type of the valve.(Medtronic core valve self expandable valve ,Edwards sapient balloon expandable valve
Study: NCT00556673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone proprionate / salmeterol xinafoate
Description: Fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg delivered via the Accuhaler® device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone proprionate / salmeterol xinafoate
Description: Fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg delivered via the Accuhaler® device.
Study: NCT00860262

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine
Description: amlodipine 5mg for the first 2w then force titration to Amlodipine 10mg for remaining 6 w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telmisartan
Description: telmisartan 80mg for the 8w, no titration required

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telmisartan and amlodipine
Description: telmisartan 80 and amlodipine 5mg for the first 2 weeks, then force titrated to telmisartan 80mg and amlodipine 10mg for the remaining 6w
Study: NCT04160156

Intervention type: DEVICE
Intervention: Long term sensor
Description: Observational study including subjects using long term sensor according to local guidelines and patients preferences
Study: NCT00757172

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: panitumumab
Study: NCT00757172

Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin

Intervention type: DRUG
Group type: OTHER
Intervention: docetaxel

Intervention type: PROCEDURE
Group type: OTHER
Intervention: neoadjuvant therapy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: therapeutic conventional surgery

Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Study: NCT02417571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring (ABPM)
Description: 24-hour ambulatory BP monitoring using TM-2430 device (A\&D Company, Tokyo, Japan)
Study: NCT01971554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8666
Description: MK-8666, capsules, oral, QD, Days 1 to 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8666
Description: MK-8666, capsules, oral, QD, Days 1 to 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8666
Description: MK-8666, capsules, oral, QD, Days 1 to 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, capsules, oral, QD, Days 1 to 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, capsules, oral, QD, Days 1 to 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, capsules, oral, QD, Days 1 to 14

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, capsules, oral, QD, Days 1 to 14
Study: NCT01806272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhGM-CSF
Description: The rhGM-CSF is prepared as a mouthwash solution,diluting 150μg in 100ml water(final concentration of 1.5μg/ml).Patient is instructed to use the solution five times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Vitamin B12
Description: Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compound Vitamin B12
Description: Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily
Study: NCT02005276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Lottery
Description: Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 4 chance of winning $5. Expected value is about $1.40 per person per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Lottery
Description: Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 4 chance of winning $5 and a 1 in 100 chance of winning $50. Expected value is about $1.40 per person per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jackpot Lottery
Description: Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 400 chance of winning $500. Expected value is about $1.40 per person per day.
Study: NCT03840577

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitorization of sedation by Bispectral Index
Description: The sedative dose administered through a continuous infusion pump will be adjusted based on the BIS value to maintain a target range of 40 to 60. If the BIS value is below the target range, the dose will be increased, and if it exceeds the range, the dose will be decreased, aiming to keep the BIS within the desired range.
Study: NCT03595254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thrive
Description: Computerized Cognitive Behavior Therapy program
Study: NCT04423211

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT
Study: NCT01790685

Intervention type: DRUG
Group type: OTHER
Intervention: dexamethasone implant

Intervention type: DRUG
Group type: OTHER
Intervention: dexamethasone implant